High cholesterol in Canada — what an LDL of 4.2 means and the statin question

You got your bloodwork back, and a number is flagged in red: LDL cholesterol, 4.2 mmol/L. Maybe your GP mentioned a statin, maybe they said "let's watch it," maybe you just saw the result in your patient portal before anyone explained it. Either way you're now trying to work out how worried to be and whether you should be taking a pill for the rest of your life. This article walks through what each number on a lipid panel actually means, why the honest answer to "is 4.2 too high?" is "it depends on your overall risk," what the statin decision really turns on, and when getting a cardiologist's eyes on your results is worth it.

The lipid panel, decoded

A standard lipid panel reports several numbers, and it helps to know what each one is telling you rather than fixating on a single figure.

• Total cholesterol — the sum of all cholesterol in your blood. On its own it's the least useful number, because it lumps the harmful and protective fractions together.
• LDL-C (low-density lipoprotein cholesterol) — the "bad" cholesterol, the fraction that drives plaque build-up in artery walls. This is the number most treatment decisions have historically been anchored to.
• HDL (high-density lipoprotein) — the "good" cholesterol that helps clear cholesterol from the circulation. Higher is generally better, though very high levels are not necessarily protective.
• Triglycerides — a blood fat strongly influenced by diet, alcohol, weight, and insulin resistance. High triglycerides often travel with low HDL.
• Non-HDL cholesterol — total cholesterol minus HDL. It captures all the atherogenic (plaque-forming) particles in one number and is often a better guide than LDL alone, especially when triglycerides are high.
• ApoB (apolipoprotein B) — a direct count of the atherogenic particles themselves. Every LDL, VLDL, and Lp(a) particle carries exactly one ApoB molecule, so ApoB measures particle number rather than the cholesterol content those particles happen to carry. Many lipid specialists now consider ApoB the single most accurate marker of cardiovascular risk, and it can reveal risk that a "reassuring" LDL misses.
• Lp(a) — lipoprotein(a) — a largely genetic, inherited lipoprotein that independently raises heart-attack and stroke risk. It stays roughly stable through life, so it only needs to be measured once in a lifetime. It is not part of the standard panel — you usually have to ask for it — and it is disproportionately elevated in South Asian populations.

Is an LDL of 4.2 high? Why there's no single answer

Here is the part that surprises most people: there is no universal LDL number above which everyone needs treatment and below which everyone is safe. The same LDL of 4.2 mmol/L can be a genuine emergency in one person and a "improve your diet and recheck" in another. What separates them is overall cardiovascular risk.

Cardiologists divide this into two situations:

Primary prevention — no heart disease yet

If you have never had a heart attack, stroke, stent, or bypass, the goal is to prevent a first event. Here the decision to treat isn't made on LDL alone — it's made on your calculated 10-year cardiovascular risk, using tools like the Framingham Risk Score as applied in the Canadian Cardiovascular Society (CCS) guidelines. That score folds in your age, sex, blood pressure, smoking status, diabetes, and cholesterol. A 4.2 LDL in a 35-year-old non-smoker with normal blood pressure sits in a very different risk bracket than the same 4.2 in a 58-year-old smoker with high blood pressure — even though the number on the page is identical.

Secondary prevention — established cardiovascular disease or diabetes

If you already have established cardiovascular disease (a prior heart attack, stroke, angina, stents, or peripheral artery disease) — or diabetes with additional risk — the calculus flips entirely. You're no longer estimating risk; the risk is proven. For these patients, guidelines call for aggressive LDL lowering to a target of 2.0 mmol/L or lower, and for the very highest-risk patients often 1.8 mmol/L or lower. Against that target, an LDL of 4.2 isn't borderline — it's more than double where it should be, and treatment is clearly indicated.

This is why the same result can't be interpreted in isolation. Your blood pressure is part of that overall risk picture too — if yours also runs high, our companion piece on what to do about high blood pressure in Canada is worth reading alongside this one, because the two risks compound.

The statin question — who actually benefits

Statins are the most studied cardiovascular drug in existence, and the honest summary is: they clearly help people at meaningful risk, and they offer little to people at genuinely low risk. The decision is risk-based, not number-based.

Under Framingham/CCS guidance, a statin is generally recommended when you have established cardiovascular disease, diabetes with risk factors, an LDL at the very high end (often ≥5.0 mmol/L, which itself raises the FH question below), or a calculated 10-year risk that crosses the treatment threshold. For someone in the low-risk primary-prevention zone, lifestyle change and monitoring may be the right first move.

Statin safety and the common concerns

Statins have a reputation shaped more by anecdote than evidence. The genuine facts: muscle aches are the most common complaint, though rigorous trials show that a large share of "statin intolerance" does not reproduce when tested in blinded conditions — the nocebo effect is real. Serious muscle injury is rare. Statins can modestly raise blood sugar and slightly increase the chance of tipping into diabetes in predisposed people, but in patients who benefit, the cardiovascular gain outweighs this. Liver enzyme elevations are usually mild; a baseline liver test before starting is standard. If one statin genuinely doesn't agree with you, switching agent or dose often solves it.

When a statin isn't enough — add-on options

Some patients don't reach their LDL target on a statin alone, or genuinely can't tolerate one. There are now well-established add-ons:

• Ezetimibe — a well-tolerated tablet that blocks cholesterol absorption in the gut; often the first add-on to a statin, and a common choice for statin-intolerant patients.
• PCSK9 inhibitors — injectable medications that lower LDL dramatically, reserved for high-risk patients not at target on maximal oral therapy, or those with familial hypercholesterolaemia.

Familial hypercholesterolaemia — the diagnosis that gets missed

If your untreated LDL is very high — roughly 5.0 mmol/L or above — one question should always be asked: could this be familial hypercholesterolaemia (FH)? FH is a common genetic condition (around 1 in 250 people) in which the body clears LDL poorly from birth, driving lifelong high cholesterol and markedly early heart disease — heart attacks in the 40s and 50s, sometimes earlier. Its defining feature is that the cholesterol is high not because of diet but because of genetics.

FH is badly under-diagnosed. The clues are a very high LDL, a personal or family history of early heart attacks or strokes, and sometimes physical signs like tendon thickening or cholesterol deposits around the eyes. If FH is suspected, it changes everything: treatment is more aggressive and started earlier, and — crucially — cascade screening is recommended, meaning first-degree relatives (parents, siblings, children) should have their cholesterol checked too, because each has a coin-flip chance of carrying the same gene. Flagging your family history is one of the most useful things you can do with a high LDL result.

The South Asian angle — why standard numbers can mislead

If you are of South Asian background, the standard interpretation of a lipid panel can under-state your real risk. South Asians tend to carry an atherogenic lipid pattern — lower HDL and higher triglycerides — which means a "normal-looking" LDL can still sit alongside a high burden of harmful particles. On top of that, Lp(a) is more often elevated in South Asian populations, and cardiovascular disease tends to strike earlier and at lower body weight than in the general Canadian population.

The practical takeaway: don't rely on LDL alone. Specifically ask for ApoB (which sees the particle burden LDL can miss) and a one-time Lp(a). We go deeper into this in our piece on heart disease risk in South Asians in Canada — if that's your background, read it. And if you're getting chest symptoms rather than just an abnormal number, our guide on chest pain and when to worry covers what warrants urgent attention.

What your GP can do

Your GP can take you a long way here, and it's worth arriving knowing what to ask for:

• Order a full lipid panel — fasting or non-fasting (both are acceptable now) — and add ApoB and a one-time Lp(a).
• Calculate your 10-year cardiovascular risk using Framingham/CCS tools, folding in blood pressure, smoking, diabetes, and family history.
• Discuss and, where indicated, start a statin — and check baseline liver enzymes first.
• Address the lifestyle foundations: saturated and trans fat reduction, soluble fibre, aerobic exercise, weight, alcohol, and smoking.

When a cardiologist or lipid specialist referral helps

Most high-cholesterol situations are managed well in primary care. But there are clear cases where specialist input genuinely changes the plan:

• Very high LDL (around 5.0 mmol/L or above) that doesn't fit a lifestyle explanation.
• Suspected familial hypercholesterolaemia — for diagnosis, aggressive treatment, and organising cascade screening of relatives.
• Statin intolerance — to sort genuine intolerance from nocebo effect and to structure add-on or alternative therapy.
• Established cardiovascular disease not at target — where ezetimibe or a PCSK9 inhibitor may be warranted to reach an LDL of ≤1.8 mmol/L.

How a specialist opinion from Ginie Health works

Here's the service in plain terms for your situation — a flagged LDL, an unanswered statin question, and no quick way to get a cardiologist's read on it in the Canadian system. You upload your lipid panel and history. Within 6 hours, for $45 CAD, you receive a written clinical opinion from a cardiologist trained at PGIMER Chandigarh or AIIMS — two of the finest medical institutions in the subcontinent. The opinion explains what your numbers mean, whether your ApoB and Lp(a) change the picture, whether a statin or add-on therapy is warranted for your risk level, and exactly what to raise with your GP.

It doesn't replace your GP or an in-person cardiologist — it makes those visits count, so you arrive knowing your real risk and the right questions. If you'd rather talk it through, a live video consultation is available for $75 CAD. No referral required for either.